Yichen Ge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yichen Ge has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Laiyu Li
Guangdong Poison Control Center, Guangzhou, China
13 shared publicationsHanlin Huang
Guangdong Poison Control Center, Guangzhou, China
12 shared publicationsBoris Reiss
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA and
11 shared publicationsChuangyi Qiu
Guangdong Poison Control Center, Guangzhou, China
11 shared publicationsMin Shen
11 shared publicationsNathaniel Rothman
11 shared publications
Latest Publications
- Open Access
The SoxC transcription factors regulate multiple early retinal lineages and function in parallel with Atoh7 to promote retinal ganglion cell genesis
Retinal development is orchestrated by a network of transcription factors that guide multipotent retinal progenitor cells (RPCs) to fate-committed lineages, ultimately producing seven major retinal cell classes. Among these, retinal ganglion cells (RGCs) serve as the sole output neurons of the retina, relaying visual and non-visual information to the brain. RGC specification requires a cascade of transcriptional regulators, including the basic helix-loop-helix (bHLH) factor Atoh7, which confers competence to RPCs, and Pou4f2 and Isl1, which drive terminal differentiation and subtype diversification. Previous studies demonstrate that the SoxC group transcription factors (Sox4, Sox11, and Sox12) are also involved in RGC genesis, but their precise integration into the Atoh7-driven regulatory hierarchy remains undefined. To address this question, we used the retina-specific Vsx2-Cre line to generate Sox4/Sox11 double conditional knockout (dcKO) and Sox4/Sox11/Atoh7 triple knockout (tKO) mice. Immunohistochemistry revealed profound lineage disruption and reduced progenitor proliferation and survival in both dcKO and tKO retinas; not only RGC genesis but also that of horizontal and amacrine (H&As) cells were severely compromised, whereas photoreceptor cells (PHCs) production increased. These results indicate that Sox4 and Sox11 are involved in the coordinated generation of the different early retinal lineages. Like the Atoh7-null retina, RGC precursors still formed in the SoxC dcKO retina, but their genesis was almost completely abolished in the tKO retina. Our findings indicate that the SoxC factors act in parallel with Atoh7 as a major upstream regulatory input to initiate RGC fate. Bulk RNA-seq revealed the SoxC-dependent transcriptional programs and signaling pathways and confirmed the lineage changes demonstrated by marker analysis. CUT&Tag analysis identified the genome-wide binding sites and thereby the target genes of Sox11, further illuminating the mechanisms underlying functions of the SoxC factors in multiple retinal cell states/types during development.
Open AccessThe SoxC transcription factors regulate multiple early retinal lineages and function in parallel with Atoh7 to promote retinal ganglion cell genesis
Retinal development is orchestrated by a network of transcription factors that guide multipotent retinal progenitor cells (RPCs) to fate-committed lineages, ultimately producing seven major retinal cell classes. Among these, retinal ganglion cells (RGCs) serve as the sole output neurons of the retina, relaying visual and non-visual information to the brain. RGC specification requires a cascade of transcriptional regulators, including the basic helix-loop-helix (bHLH) factor Atoh7, which confers competence to RPCs, and Pou4f2 and Isl1, which drive terminal differentiation and subtype diversification. Previous studies demonstrate that the SoxC group transcription factors (Sox4, Sox11, and Sox12) are also involved in RGC genesis, but their precise integration into the Atoh7-driven regulatory hierarchy remains undefined. To address this question, we used the retina-specific Vsx2-Cre line to generate Sox4/Sox11 double conditional knockout (dcKO) and Sox4/Sox11/Atoh7 triple knockout (tKO) mice. Immunohistochemistry revealed profound lineage disruption and reduced progenitor proliferation and survival in both dcKO and tKO retinas; not only RGC genesis but also that of horizontal and amacrine (H&As) cells were severely compromised, whereas photoreceptor cells (PHCs) production increased. These results indicate that Sox4 and Sox11 are involved in the coordinated generation of the different early retinal lineages. Like the Atoh7-null retina, RGC precursors still formed in the SoxC dcKO retina, but their genesis was almost completely abolished in the tKO retina. Our findings indicate that the SoxC factors act in parallel with Atoh7 as a major upstream regulatory input to initiate RGC fate. Bulk RNA-seq revealed the SoxC-dependent transcriptional programs and signaling pathways and confirmed the lineage changes demonstrated by marker analysis. CUT&Tag analysis identified the genome-wide binding sites and thereby the target genes of Sox11, further illuminating the mechanisms underlying functions of the SoxC factors in multiple retinal cell states/types during development.
- Open Access
- 30 January 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (5) , 2151-2176
Key transcription factors influence the epigenetic landscape to regulate retinal cell differentiation
How the diverse neural cell types emerge from multipotent neural progenitor cells during central nervous system development remains poorly understood. Recent scRNA-seq studies have delineated the developmental trajectories of individual neural cell types in many neural systems including the neural retina. Further understanding of the formation of neural cell diversity requires knowledge about how the epigenetic landscape shifts along individual cell lineages and how key transcription factors regulate these changes. In this study, we dissect the changes in the epigenetic landscape during early retinal cell differentiation by scATAC-seq and identify globally the enhancers, enriched motifs, and potential interacting transcription factors underlying the cell state/type specific gene expression in individual lineages. Using CUT&Tag, we further identify the enhancers bound directly by four key transcription factors, Otx2, Atoh7, Pou4f2 and Isl1, including those dependent on Atoh7, and uncover the sequential and combinatorial interactions of these factors with the epigenetic landscape to control gene expression along individual retinal cell lineages such as retinal ganglion cells (RGCs). Our results reveal a general paradigm in which transcription factors collaborate and compete to regulate the emergence of distinct retinal cell types such as RGCs from multipotent retinal progenitor cells (RPCs).
- 30 January 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (5) , 2151-2176
Open AccessKey transcription factors influence the epigenetic landscape to regulate retinal cell differentiation
How the diverse neural cell types emerge from multipotent neural progenitor cells during central nervous system development remains poorly understood. Recent scRNA-seq studies have delineated the developmental trajectories of individual neural cell types in many neural systems including the neural retina. Further understanding of the formation of neural cell diversity requires knowledge about how the epigenetic landscape shifts along individual cell lineages and how key transcription factors regulate these changes. In this study, we dissect the changes in the epigenetic landscape during early retinal cell differentiation by scATAC-seq and identify globally the enhancers, enriched motifs, and potential interacting transcription factors underlying the cell state/type specific gene expression in individual lineages. Using CUT&Tag, we further identify the enhancers bound directly by four key transcription factors, Otx2, Atoh7, Pou4f2 and Isl1, including those dependent on Atoh7, and uncover the sequential and combinatorial interactions of these factors with the epigenetic landscape to control gene expression along individual retinal cell lineages such as retinal ganglion cells (RGCs). Our results reveal a general paradigm in which transcription factors collaborate and compete to regulate the emergence of distinct retinal cell types such as RGCs from multipotent retinal progenitor cells (RPCs).
- Open Access
- 5 March 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-20
Single cell transcriptomics reveals lineage trajectory of retinal ganglion cells in wild-type and Atoh7-null retinas
Atoh7 has been believed to be essential for establishing the retinal ganglion cell (RGC) lineage, and Pou4f2 and Isl1 are known to regulate RGC specification and differentiation. Here we report our further study of the roles of these transcription factors. Using bulk RNA-seq, we identify genes regulated by the three transcription factors, which expand our understanding of the scope of downstream events. Using scRNA-seq on wild-type and mutant retinal cells, we reveal a transitional cell state of retinal progenitor cells (RPCs) co-marked by Atoh7 and other genes for different lineages and shared by all early retinal lineages. We further discover the unexpected emergence of the RGC lineage in the absence of Atoh7. We conclude that competence of RPCs for different retinal fates is defined by lineage-specific genes co-expressed in the transitional state and that Atoh7 defines the RGC competence and collaborates with other factors to shepherd transitional RPCs to the RGC lineage.
- 5 March 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-20
Open AccessSingle cell transcriptomics reveals lineage trajectory of retinal ganglion cells in wild-type and Atoh7-null retinas
Atoh7 has been believed to be essential for establishing the retinal ganglion cell (RGC) lineage, and Pou4f2 and Isl1 are known to regulate RGC specification and differentiation. Here we report our further study of the roles of these transcription factors. Using bulk RNA-seq, we identify genes regulated by the three transcription factors, which expand our understanding of the scope of downstream events. Using scRNA-seq on wild-type and mutant retinal cells, we reveal a transitional cell state of retinal progenitor cells (RPCs) co-marked by Atoh7 and other genes for different lineages and shared by all early retinal lineages. We further discover the unexpected emergence of the RGC lineage in the absence of Atoh7. We conclude that competence of RPCs for different retinal fates is defined by lineage-specific genes co-expressed in the transitional state and that Atoh7 defines the RGC competence and collaborates with other factors to shepherd transitional RPCs to the RGC lineage.
- 28 August 2020
- Published by Wiley in Developmental Dynamics
- Vol. 249 (12) , 1514-1528
Two new genetically modified mouse alleles labeling distinct phases of retinal ganglion cell development by fluorescent proteins
Background: During development, all retinal cell types arise from retinal progenitor cells (RPCs) in a step‐wise fashion. Atoh7 and Pou4f2 mark, and function in, two phases of retinal ganglion cell (RGC) genesis; Atoh7 functions in a subpopulation of RPCs to render them competent for the RGC fate, whereas Pou4f2 participates in RGC fate specification and RGC differentiation. Despite extensive research on their roles, the properties of the two phases represented by these two factors have not been well studied, likely due to the retinal cellular heterogeneity.Results: In this report, we describe two novel knock‐in mouse alleles, Atoh7zsGreenCreERT2 and Pou4f2FlagtdTomato, which labeled retinal cells in the two phases of RGC development by fluorescent proteins. Also, the Atoh7zsGreenCreERT2 allele allowed for indirect labeling of RGCs and other cell types upon tamoxifen induction in a dose‐dependent manner. Further, these alleles could be used to purify retinal cells in the different phases by fluorescence assisted cell sorting (FACS). Single cell RNA‐seq analysis of purified cells from Atoh7zsGreenCreERT2 retinas further validated that this allele labeled both transitional/competent RPCs and their progenies including RGCs.Conclusions: Thus, these two alleles are very useful tools for studying the molecular and genetic mechanisms underlying RGC formation.
- 28 August 2020
- Published by Wiley in Developmental Dynamics
- Vol. 249 (12) , 1514-1528
Two new genetically modified mouse alleles labeling distinct phases of retinal ganglion cell development by fluorescent proteins
Background: During development, all retinal cell types arise from retinal progenitor cells (RPCs) in a step‐wise fashion. Atoh7 and Pou4f2 mark, and function in, two phases of retinal ganglion cell (RGC) genesis; Atoh7 functions in a subpopulation of RPCs to render them competent for the RGC fate, whereas Pou4f2 participates in RGC fate specification and RGC differentiation. Despite extensive research on their roles, the properties of the two phases represented by these two factors have not been well studied, likely due to the retinal cellular heterogeneity.Results: In this report, we describe two novel knock‐in mouse alleles, Atoh7zsGreenCreERT2 and Pou4f2FlagtdTomato, which labeled retinal cells in the two phases of RGC development by fluorescent proteins. Also, the Atoh7zsGreenCreERT2 allele allowed for indirect labeling of RGCs and other cell types upon tamoxifen induction in a dose‐dependent manner. Further, these alleles could be used to purify retinal cells in the different phases by fluorescence assisted cell sorting (FACS). Single cell RNA‐seq analysis of purified cells from Atoh7zsGreenCreERT2 retinas further validated that this allele labeled both transitional/competent RPCs and their progenies including RGCs.Conclusions: Thus, these two alleles are very useful tools for studying the molecular and genetic mechanisms underlying RGC formation.
- 26 June 2019
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 32 (8) , 1572-1582
GMDTC Chelating Agent Attenuates Cisplatin-Induced Systemic Toxicity without Affecting Antitumor Efficacy
Cisplatin is a platinum-based chemotherapeutic drug widely used in the treatment of various cancers such as testicular, ovarian, lung, bladder, and cervical cancers. However, its use and the dosage range applied have been limited by severe side effects (e.g. nephrotoxicity and ototoxicity) and by the development of resistance to cisplatin in patients during treatment. Metal chelators have shown promising potential in overcoming these problems often associated with platinum drugs. Previously, a new chelating agent, sodium (S)-2-(dithiocarboxylato ((2S,3R,4R,5R)-2,3,4,5,6 pentahydroxyhexyl) amino)-4(methylthio) butanoate (GMDTC), was developed. In this study, we examined the effect of GMDTC in modifying cisplatin-induced toxicities following in vitro and in vivo exposures. GMDTC treatment dramatically reduced cisplatin-induced apoptosis and cytotoxicity in HK2 cells by decreasing the amount of intracellular platinum. In the 4T1 breast cancer mouse model, GMDTC reduced cisplatin-induced nephrotoxicity by reducing cisplatin deposition in the kidney. GMDTC attenuated cisplatin-induced elevations in BUN and plasma CRE, ameliorated renal tubular dilation and vacuolation, and prevented necrosis of glomeruli and renal tubular cells. GMDTC also inhibited cisplatin-induced ototoxicity as shown by improved hearing loss which was assessed using the auditory brainstem response (ABR) test. Furthermore, GMDTC attenuated cisplatin-induced hematotoxicity and hepatotoxicity. Importantly, co-treatment of cisplatin with GMDTC did not affect cisplatin antitumor efficacy. Tumor growth, size, and metastasis were all comparable between the cisplatin only and cisplatin-GMDTC co-treatment groups. In conclusion, the current study suggests that GMDTC reduces cisplatin-induced systemic toxicity by preventing the accumulation and assisting in the removal of intracellular cisplatin, without compromising cisplatin therapeutic activity. These results support the development of GMDTC as a chemotherapy protector and rescue agent to overcome the toxicity of and resistance to platinum-based antineoplastic drugs.
- 26 June 2019
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 32 (8) , 1572-1582
GMDTC Chelating Agent Attenuates Cisplatin-Induced Systemic Toxicity without Affecting Antitumor Efficacy
Cisplatin is a platinum-based chemotherapeutic drug widely used in the treatment of various cancers such as testicular, ovarian, lung, bladder, and cervical cancers. However, its use and the dosage range applied have been limited by severe side effects (e.g. nephrotoxicity and ototoxicity) and by the development of resistance to cisplatin in patients during treatment. Metal chelators have shown promising potential in overcoming these problems often associated with platinum drugs. Previously, a new chelating agent, sodium (S)-2-(dithiocarboxylato ((2S,3R,4R,5R)-2,3,4,5,6 pentahydroxyhexyl) amino)-4(methylthio) butanoate (GMDTC), was developed. In this study, we examined the effect of GMDTC in modifying cisplatin-induced toxicities following in vitro and in vivo exposures. GMDTC treatment dramatically reduced cisplatin-induced apoptosis and cytotoxicity in HK2 cells by decreasing the amount of intracellular platinum. In the 4T1 breast cancer mouse model, GMDTC reduced cisplatin-induced nephrotoxicity by reducing cisplatin deposition in the kidney. GMDTC attenuated cisplatin-induced elevations in BUN and plasma CRE, ameliorated renal tubular dilation and vacuolation, and prevented necrosis of glomeruli and renal tubular cells. GMDTC also inhibited cisplatin-induced ototoxicity as shown by improved hearing loss which was assessed using the auditory brainstem response (ABR) test. Furthermore, GMDTC attenuated cisplatin-induced hematotoxicity and hepatotoxicity. Importantly, co-treatment of cisplatin with GMDTC did not affect cisplatin antitumor efficacy. Tumor growth, size, and metastasis were all comparable between the cisplatin only and cisplatin-GMDTC co-treatment groups. In conclusion, the current study suggests that GMDTC reduces cisplatin-induced systemic toxicity by preventing the accumulation and assisting in the removal of intracellular cisplatin, without compromising cisplatin therapeutic activity. These results support the development of GMDTC as a chemotherapy protector and rescue agent to overcome the toxicity of and resistance to platinum-based antineoplastic drugs.
- 1 September 2018
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 355, 164-173
Mapping dynamic histone modification patterns during arsenic-induced malignant transformation of human bladder cells
- 1 September 2018
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 355, 164-173
Mapping dynamic histone modification patterns during arsenic-induced malignant transformation of human bladder cells
- Open Access
- 2 May 2016
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 37 (7) , 692-700
Comparison of hematological alterations and markers of B-cell activation in workers exposed to benzene, formaldehyde and trichloroethylene
Benzene, formaldehyde (FA) and trichloroethylene (TCE) are ubiquitous chemicals in workplaces and the general environment. Benzene is an established myeloid leukemogen and probable lymphomagen. FA is classified as a myeloid leukemogen but has not been associated with non-Hodgkin lymphoma (NHL), whereas TCE has been associated with NHL but not myeloid leukemia. Epidemiologic associations between FA and myeloid leukemia, and between benzene, TCE and NHL are, however, still debated. Previously, we showed that these chemicals are associated with hematotoxicity in cross-sectional studies of factory workers in China, which included extensive personal monitoring and biological sample collection. Here, we compare and contrast patterns of hematotoxicity, monosomy 7 in myeloid progenitor cells (MPCs), and B-cell activation biomarkers across these studies to further evaluate possible mechanisms of action and consistency of effects with observed hematologic cancer risks. Workers exposed to benzene or FA, but not TCE, showed declines in cell types derived from MPCs, including granulocytes and platelets. Alterations in lymphoid cell types, including B cells and CD4+ T cells, and B-cell activation markers were apparent in workers exposed to benzene or TCE. Given that alterations in myeloid and lymphoid cell types are associated with hematological malignancies, our data provide biologic insight into the epidemiological evidence linking benzene and FA exposure with myeloid leukemia risk, and TCE and benzene exposure with NHL risk.
- 2 May 2016
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 37 (7) , 692-700
Open AccessComparison of hematological alterations and markers of B-cell activation in workers exposed to benzene, formaldehyde and trichloroethylene
Benzene, formaldehyde (FA) and trichloroethylene (TCE) are ubiquitous chemicals in workplaces and the general environment. Benzene is an established myeloid leukemogen and probable lymphomagen. FA is classified as a myeloid leukemogen but has not been associated with non-Hodgkin lymphoma (NHL), whereas TCE has been associated with NHL but not myeloid leukemia. Epidemiologic associations between FA and myeloid leukemia, and between benzene, TCE and NHL are, however, still debated. Previously, we showed that these chemicals are associated with hematotoxicity in cross-sectional studies of factory workers in China, which included extensive personal monitoring and biological sample collection. Here, we compare and contrast patterns of hematotoxicity, monosomy 7 in myeloid progenitor cells (MPCs), and B-cell activation biomarkers across these studies to further evaluate possible mechanisms of action and consistency of effects with observed hematologic cancer risks. Workers exposed to benzene or FA, but not TCE, showed declines in cell types derived from MPCs, including granulocytes and platelets. Alterations in lymphoid cell types, including B cells and CD4+ T cells, and B-cell activation markers were apparent in workers exposed to benzene or TCE. Given that alterations in myeloid and lymphoid cell types are associated with hematological malignancies, our data provide biologic insight into the epidemiological evidence linking benzene and FA exposure with myeloid leukemia risk, and TCE and benzene exposure with NHL risk.
- Open Access
- 20 May 2015
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 146 (2) , 354-362
Interactive Effects of N6AMT1 and As3MT in Arsenic Biomethylation
In humans, arsenic is primarily metabolized by arsenic (+3 oxidation state) methyltransferase (As3MT) to yield both trivalent and pentavalent methylated metabolites. We recently reported that the putative N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) can biotransform monomethylarsonous acid (MMAIII) to dimethylarsinic acid, conferring resistance of human cells to arsenic exposure. To further decipher the role of N6AMT1 and its interaction with As3MT in arsenic biomethylation, we examined the relative contribution of N6AMT1 and As3MT in metabolizing arsenic using several newly modified UROtsa human urothelial cells, ie, UROtsa cells with either a constant level of N6AMT1 or As3MT in combination with an inducible level of As3MT or N6AMT1, respectively. Our analysis confirmed the involvement of N6AMT1 in MMAIII biomethylation but not for inorganic arsenic. In a comparable level of N6AMT1 and As3MT, the effect of N6AMT1 mediated MMAIII biomethylation was obscured by the action of As3MT. Furthermore, we showed that the levels of N6AMT1 and As3MT proteins varied among and within human normal and cancerous tissues. Overall, the data showed that N6AMT1 has a role in MMAIII biomethylation, but its effect is relatively minor and limited compared with As3MT. In addition, the varied levels and distributions of N6AMT1 and As3MT among human tissues may potentially contribute to the tissue specificity and susceptibility to arsenic toxicity and carcinogenicity.
- 20 May 2015
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 146 (2) , 354-362
Open AccessInteractive Effects of N6AMT1 and As3MT in Arsenic Biomethylation
In humans, arsenic is primarily metabolized by arsenic (+3 oxidation state) methyltransferase (As3MT) to yield both trivalent and pentavalent methylated metabolites. We recently reported that the putative N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) can biotransform monomethylarsonous acid (MMAIII) to dimethylarsinic acid, conferring resistance of human cells to arsenic exposure. To further decipher the role of N6AMT1 and its interaction with As3MT in arsenic biomethylation, we examined the relative contribution of N6AMT1 and As3MT in metabolizing arsenic using several newly modified UROtsa human urothelial cells, ie, UROtsa cells with either a constant level of N6AMT1 or As3MT in combination with an inducible level of As3MT or N6AMT1, respectively. Our analysis confirmed the involvement of N6AMT1 in MMAIII biomethylation but not for inorganic arsenic. In a comparable level of N6AMT1 and As3MT, the effect of N6AMT1 mediated MMAIII biomethylation was obscured by the action of As3MT. Furthermore, we showed that the levels of N6AMT1 and As3MT proteins varied among and within human normal and cancerous tissues. Overall, the data showed that N6AMT1 has a role in MMAIII biomethylation, but its effect is relatively minor and limited compared with As3MT. In addition, the varied levels and distributions of N6AMT1 and As3MT among human tissues may potentially contribute to the tissue specificity and susceptibility to arsenic toxicity and carcinogenicity.
- 1 March 2015
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 283 (3) , 198-209
Arsenic responsive microRNAs in vivo and their potential involvement in arsenic-induced oxidative stress
- 1 March 2015
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 283 (3) , 198-209
Arsenic responsive microRNAs in vivo and their potential involvement in arsenic-induced oxidative stress